Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Fernández-Mateos J, Pérez-García J, Seijas-Tamayo R, Mesía R, Rubió-Casadevall J, García-Girón C, Iglesias L, Carral Maseda A, Adansa Klain JC, Taberna M, Vazquez S, Gómez MA, Del Barco E, Ocana A, González-Sarmiento R, Cruz-Hernández JJ. Fernández-Mateos J, et al. Sci Rep. 2020 Oct 6;10(1):16634. doi: 10.1038/s41598-020-72927-2. Sci Rep. 2020. PMID: 33024167 Free PMC article.
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
Mesía R, Garcia-Saenz JA, Lozano A, Pastor M, Grau JJ, Martínez-Trufero J, Lambeaz J, Martínez-Galán J, Mel JR, González B, Vázquez S, Mañós M, Taberna M, Cirauqui B, Del Barco E, Casado E, Rubió-Casadevall J, Rodríguez-Jaráiz A, Cruz JJ; Spanish Head And Neck Cancer Cooperative Group (Study TTCC-2007/02). Mesía R, et al. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):473-480. doi: 10.1016/j.ijrobp.2016.11.016. Epub 2016 Nov 17. Int J Radiat Oncol Biol Phys. 2017. PMID: 28011050 Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, Rubió-Casadevall J, Plana Serrahima M, Ponce Ortega JM, Planas Toledano I, Caballero J, Marruecos Querol J, Iglesias Docampo L, Lambea Sorrosal J, Adansa JC, Mesía Nin R; Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Martínez-Trufero J, et al. Clin Transl Oncol. 2021 Aug;23(8):1666-1677. doi: 10.1007/s12094-021-02567-z. Epub 2021 Apr 19. Clin Transl Oncol. 2021. PMID: 33876416 Clinical Trial.
SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, Iglesias Rey L, Rubió-Casadevall J, Arrazubi V, Mesía R. Rueda Domínguez A, et al. Among authors: rubio casadevall j. Clin Transl Oncol. 2022 Apr;24(4):670-680. doi: 10.1007/s12094-022-02814-x. Epub 2022 Mar 18. Clin Transl Oncol. 2022. PMID: 35303267 Free PMC article.
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Hitt R, Mesía R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, Rubió-Casadevall J, Martínez-Trufero J, Morillo EDB, García Girón C, Vázquez Estévez S, Cirauqui B, Cruz-Hernández JJ. Hitt R, et al. Among authors: rubio casadevall j. Oral Oncol. 2022 Nov;134:106087. doi: 10.1016/j.oraloncology.2022.106087. Epub 2022 Sep 18. Oral Oncol. 2022. PMID: 36126605 Clinical Trial.
Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population.
Marruecos-Querol J, Rubió-Casadevall J, Lozano A, Buxó M, Puigdemont M, Linares I, Planas I, Vayreda J, Cirauqui B, Taberna M, Quiroga V, Tobed M, Borés A, Recalde S, Saigi M, Felip E, Eraso A, Mesía R. Marruecos-Querol J, et al. Among authors: rubio casadevall j. Clin Transl Oncol. 2023 Aug;25(8):2384-2392. doi: 10.1007/s12094-023-03121-9. Epub 2023 Mar 21. Clin Transl Oncol. 2023. PMID: 36943650
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, Iglesias Docampo L, Pérez Segura P, Ceballos Lenza I, Gutiérrez Calderón V, Fuster Salvà J, Pena Álvarez C, Hernandez I, Del Barco Morillo E, Chaves Conde M, Martínez Galán J, Durán Sánchez M, Quiroga V, Ortega E, Mesia R. Rubió-Casadevall J, et al. Front Oncol. 2023 Aug 1;13:1226939. doi: 10.3389/fonc.2023.1226939. eCollection 2023. Front Oncol. 2023. PMID: 37601652 Free PMC article.
41 results